Amneal Pharmaceuticals stock hits a USD 21.46 52-week high

Published on 10/27/2026 at 21:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 9.90 percent to USD 796.20 million on July 30, 2026. Amneal Pharmaceuticals stock costs EUR 19.10 on October 27, 2026.

52-week high and target date

Amneal Pharmaceuticals reached a 52-week high on October 27, 2026.
JPMorgan lifted its target to USD 24.00 on October 22, 2026.
Amneal Pharmaceuticals stock costs EUR 19.10 at Lang & Schwarz on October 27, 2026 at 9:44 p.m. CET.
Third-quarter results are scheduled for November 3, 2026.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals (ISIN US03168L1052) touched a 52-week high of USD 21.46 on October 27, 2026, with the last Nasdaq price at USD 21.44 at 4:00 p.m. ET. Markets Insider reported on October 22, 2026 that JPMorgan analyst Chris Schott raised the price target from USD 22.00 to USD 24.00 while retaining an Overweight rating. Amneal Pharmaceuticals was trading at EUR 19.10 at Lang & Schwarz on October 27, 2026 at 9:44 p.m. CET.

Revenue growth sets the earnings baseline

Amneal's second-quarter 2026 revenue reached USD 796.20 million, up 9.90 percent year over year. The company's adjusted earnings per share came to USD 0.30, compared with a consensus estimate of USD 0.24, according to Yahoo Finance on July 30, 2026.

The quarterly result also set a useful operating reference. Adjusted EBITDA was USD 206.00 million, up 12.00 percent year over year, while adjusted gross margin reached 46.20 percent, an increase of 60 basis points.

A 0.09 percent gap to the high

Amneal's primary-market quote of USD 21.44 stood 0.09 percent below its USD 21.46 52-week high and 114.71 percent above its USD 9.99 52-week low on October 27, 2026. Trading volume was 2,548,281 shares, and the market capitalization was USD 6.8 billion.

USD 24.00 target and November 3 results

JPMorgan's USD 24.00 target was 11.94 percent above the USD 21.44 Nasdaq price on October 27, 2026. Amneal Pharmaceuticals announced on October 8, 2026 that it will publish third-quarter 2026 results before market open on November 3, 2026, followed by an 8:30 a.m. ET webcast.

The next report gives investors a defined checkpoint for the outlook. For fiscal year 2026, management guidance cited in the October 2026 market coverage calls for adjusted earnings per share of USD 0.96 to USD 1.06.

Comparison with peers

Amneal Pharmaceuticals: price-to-earnings ratio 43.98, market capitalization USD 6.8 billion.

Teva Pharmaceutical Industries: up 1.10 percent, price-to-earnings ratio 67.32, market capitalization USD 47.1 billion.

Viatris: up 2.35 percent, price-to-earnings ratio minus 52.00, market capitalization USD 21.5 billion.

Euro quote and investor frame

The euro quote places the German trading perspective alongside Amneal's Nasdaq valuation and the upcoming November 3 reporting date. The further course of trading is shown by the continuously updated real-time quote of Amneal Pharmaceuticals stock.